Elixir: Another Sirtuin IPO on Calendar

Another sirtuin company is looking to raise funding in an IPO. Also based in Cambridge Massachusetts, Elixir Pharmaceuticals has a couple of other drug targets other than Sirtuins that it has licensed from other companies. One of the most interesting aspects of the pending Elixir IPO is that one of its co-founders recently defected from Elixir to join SIRT:

http://www.xconomy.com/2007/11/19/sir2-roads-diverged-elixir-co-founder-joins-rival-sirtris/

It seems to speak very highly of the potential of Sirtris that Leonard Guarente, who some feel may be a future Nobelist, left his own company to join its main rival in the area of Sirtuins. Mr. Guarante is credited with discovering that the activation level of the Sir2 enzyme increases the lifespan of mice, yeast, worms, and other organisms.